Technical Analysis for CYTO - Altamira Therapeutics Ltd.

Grade Last Price % Change Price Change
F 1.77 -2.21% -0.04
CYTO closed down 3.21 percent on Monday, October 18, 2021, on 74 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical CYTO trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup -1.10%
Boomer Sell Setup Bearish Swing Setup -1.10%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.10%
Calm After Storm Range Contraction -1.10%
Inside Day Range Contraction -1.10%
Wide Bands Range Expansion -1.10%
MACD Bullish Signal Line Cross Bullish -4.28%
Calm After Storm Range Contraction -4.28%
Inside Day Range Contraction -4.28%
Wide Bands Range Expansion -4.28%
Older End-of-Day Signals for CYTO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support 9 minutes ago
60 Minute Opening Range Breakdown about 1 hour ago
Down 3% about 1 hour ago
Boomer Sell Entry about 1 hour ago
Non-ADX 1,2,3,4 Bearish Retracement Entry about 1 hour ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Altamira Therapeutics Ltd. Description

Altamira Therapeutics is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne pathogens and allergens (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol 'EARS.'


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Allergy Nervous System Auditory System Otology Tinnitus Inner Ear Sensory Systems

Is CYTO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.6
52 Week Low 0.78
Average Volume 290,035
200-Day Moving Average 3.11
50-Day Moving Average 2.41
20-Day Moving Average 1.96
10-Day Moving Average 1.78
Average True Range 0.16
ADX 30.78
+DI 19.18
-DI 28.94
Chandelier Exit (Long, 3 ATRs) 2.09
Chandelier Exit (Short, 3 ATRs) 2.01
Upper Bollinger Bands 2.41
Lower Bollinger Band 1.51
Percent B (%b) 0.33
BandWidth 45.81
MACD Line -0.19
MACD Signal Line -0.21
MACD Histogram 0.0193
Fundamentals Value
Market Cap 12.83 Million
Num Shares 7.09 Million
EPS -1.33
Price-to-Earnings (P/E) Ratio -1.36
Price-to-Sales 0.00
Price-to-Book 1.37
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.96
Resistance 3 (R3) 1.96 1.92 1.93
Resistance 2 (R2) 1.92 1.88 1.91 1.93
Resistance 1 (R1) 1.86 1.85 1.89 1.86 1.92
Pivot Point 1.82 1.82 1.83 1.82 1.82
Support 1 (S1) 1.76 1.78 1.79 1.76 1.70
Support 2 (S2) 1.72 1.75 1.72 1.69
Support 3 (S3) 1.66 1.72 1.69
Support 4 (S4) 1.66